Clinical Trial Update: Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs

View source ↗

Summary

This completed clinical trial evaluates how patients with Polypoidal Choroidal Vasculopathy respond to ranibizumab, including potential associations with SNPs.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polypoidal Choroidal Vasculopathy

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Nihon University | Conditions: Polypoidal Choroidal Vasculopathy | Status: COMPLETED